Nothing Special   »   [go: up one dir, main page]

PL3292116T3 - 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac - Google Patents

3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac

Info

Publication number
PL3292116T3
PL3292116T3 PL16704357T PL16704357T PL3292116T3 PL 3292116 T3 PL3292116 T3 PL 3292116T3 PL 16704357 T PL16704357 T PL 16704357T PL 16704357 T PL16704357 T PL 16704357T PL 3292116 T3 PL3292116 T3 PL 3292116T3
Authority
PL
Poland
Prior art keywords
amido
bicyclic
aryl
hdac inhibitors
hydroxamic acids
Prior art date
Application number
PL16704357T
Other languages
English (en)
Inventor
Xiaozhang Zheng
Pui Yee Ng
Bingsong Han
Jennifer R. Thomason
Mary-Margaret Zablocki
Cuixian Liu
Heather Davis
Aleksandra Rudnitskaya
David LANCIA Jr.
David S. MILLAN
Matthew W. Martin
Original Assignee
Valo Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valo Health, Inc. filed Critical Valo Health, Inc.
Publication of PL3292116T3 publication Critical patent/PL3292116T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL16704357T 2015-02-02 2016-02-02 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac PL3292116T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562110716P 2015-02-02 2015-02-02
US201562205438P 2015-08-14 2015-08-14
PCT/US2016/016200 WO2016126724A1 (en) 2015-02-02 2016-02-02 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP16704357.9A EP3292116B8 (en) 2015-02-02 2016-02-02 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors

Publications (1)

Publication Number Publication Date
PL3292116T3 true PL3292116T3 (pl) 2022-02-21

Family

ID=55353351

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16704357T PL3292116T3 (pl) 2015-02-02 2016-02-02 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac

Country Status (27)

Country Link
US (32) US10214500B2 (pl)
EP (3) EP3253747B1 (pl)
JP (1) JP6668362B2 (pl)
KR (1) KR102633628B1 (pl)
CN (3) CN114057765A (pl)
AU (4) AU2016215431B2 (pl)
BR (1) BR112017016493B1 (pl)
CA (2) CA2990165C (pl)
CL (1) CL2017001968A1 (pl)
CO (1) CO2017007863A2 (pl)
DK (1) DK3292116T3 (pl)
EA (2) EA201792673A1 (pl)
EC (1) ECSP17055491A (pl)
ES (2) ES2903523T3 (pl)
HK (2) HK1251550A1 (pl)
HU (1) HUE057623T2 (pl)
IL (4) IL280856B (pl)
MA (1) MA42032A (pl)
MX (2) MX2020003488A (pl)
MY (1) MY191591A (pl)
PH (1) PH12017501383A1 (pl)
PL (1) PL3292116T3 (pl)
PT (1) PT3292116T (pl)
SA (1) SA517382027B1 (pl)
SG (4) SG10202100915RA (pl)
TW (6) TWI697486B (pl)
WO (4) WO2016126725A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3292116T3 (pl) 2015-02-02 2022-02-21 Valo Health, Inc. 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
SG11201707418WA (en) 2015-03-13 2017-10-30 Forma Therapeutics Inc Alpha-cinnamide compounds and compositions as hdac8 inhibitors
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN110913858B (zh) 2017-05-17 2024-09-24 戴纳立制药公司 激酶抑制剂及其用途
US11161825B2 (en) * 2017-08-15 2021-11-02 Bayer Aktiengesellschaft 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides
WO2020096916A2 (en) 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
CN111848591B (zh) * 2019-04-25 2022-03-18 成都先导药物开发股份有限公司 Hdac抑制剂及其制备方法和用途
CN114846012B (zh) 2019-09-27 2024-01-26 武田药品工业株式会社 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物
CN113527206B (zh) * 2020-04-17 2022-12-30 上海中泽医药科技有限公司 一种苯并氮杂环类化合物、其制备方法及用途
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
CN112691706A (zh) * 2020-12-23 2021-04-23 中触媒新材料股份有限公司 一种乙醇制乙腈催化剂的再生方法
KR20240013098A (ko) 2021-04-23 2024-01-30 테나야 테라퓨틱스, 인코포레이티드 확장성 심근병증의 치료에 사용하기 위한 hdac6 억제제
MX2023012875A (es) 2021-05-04 2024-01-12 Tenaya Therapeutics Inc Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
JP2024533236A (ja) * 2021-09-06 2024-09-12 タイペイ・メディカル・ユニバーシティ ヒストン脱アセチル化酵素６及び熱ショックタンパク質９０の二重阻害剤
WO2023081328A1 (en) * 2021-11-04 2023-05-11 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides
WO2024104823A1 (en) 2022-11-16 2024-05-23 Basf Se New substituted tetrahydrobenzoxazepine

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557425C2 (de) 1975-12-19 1987-03-19 C.H. Boehringer Sohn, 6507 Ingelheim 11-Oxo-11-H-pyrido[2,1-b]-chinazolin-2-carbonsäure und ihre Salze, Verfahren zu ihrer Herstellung und Arzneimittel
DE3704203A1 (de) 1987-02-11 1988-08-25 Boehringer Ingelheim Kg Verwendung von oxochinazolinderivaten bei der behandlung der hyperurikaemie
US5244911A (en) 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US5153185A (en) 1991-04-16 1992-10-06 Merck & Co., Inc. 2-phenanthridonyl carbapenems
US5294610A (en) 1992-10-15 1994-03-15 Merck & Co. Inc. 2-(aza-9-fluorenonyl)carbapenem antibacterial agents
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP0638071B1 (en) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5714518A (en) 1993-01-15 1998-02-03 Agouron Pharmaceuticals HIV protease inhibitors and methods of making the same
US5384317A (en) 1993-08-02 1995-01-24 Merck & Co., Inc. Bridged biphenyl carbapenem compounds, compositions containing such compounds and methods of use
US6872542B1 (en) 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
ES2225834T3 (es) 1993-11-18 2005-03-16 Washington University Compuestos y composiciones farmaceuticas para el tratamiento y profilaxis de infecciones bacterianas.
US6110913A (en) 1994-01-04 2000-08-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5532261A (en) 1994-12-12 1996-07-02 Merck & Co., Inc. Carbapenem antibiotics, compositions containing such compounds and methods of use
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997005130A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia. S.A. New pyrimidone derivatives with antifungal activity
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
EP0845026A1 (de) 1996-06-19 1998-06-03 CALL, Hans-Peter Dr. Mehrkomponentensystem zur verwendung mit waschaktiven substanzen
DE19726241A1 (de) 1997-06-20 1998-12-24 Call Krimhild Erweitertes enzymatisches Multikomponentensystem zur Behandlung von Abwässern, zur Herstellung von Holzverbundstoffen, zum Deinken von Altpapier, Colour stripping von Altpapier, zum Einsatz als Oxidationssystem bei der organischen Synthese und zum Einsatz bei der Kohleverflüssigung
IL121748A0 (en) 1997-09-11 1998-02-22 Yeda Res & Dev Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6180640B1 (en) 1998-06-25 2001-01-30 Sepracor, Inc. Di- and tetra-hydroquinoline-indole antimicrobial agents, uses and compositions related thereto
JP2000044562A (ja) 1998-07-31 2000-02-15 Kyowa Hakko Kogyo Co Ltd ピロロフタルイミド誘導体
US6288099B1 (en) 1998-12-04 2001-09-11 American Home Products Corporation Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
BR9915900A (pt) 1998-12-04 2001-08-21 American Home Prod Composto, composição farmacêutica, e, processo para tratar ou inibir distúrbios associados com contração da musculatura lisa.
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
JP2000357809A (ja) 1999-06-15 2000-12-26 Fuji Photo Film Co Ltd 光電変換材料、光電変換素子及びポリメチン色素
JP4162106B2 (ja) 1999-06-17 2008-10-08 富士フイルム株式会社 光電変換素子および光電気化学電池ならびに金属錯体色素
AU6525300A (en) 1999-08-13 2001-03-13 Sepracor, Inc. Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
FR2809391B1 (fr) 2000-05-29 2003-05-09 Rhodia Chimie Sa Nouveau mortier phosphomagnesien, procede d'obtention de ce mortier
JP4340437B2 (ja) 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
AU2002214222A1 (en) 2000-11-01 2002-05-15 Yeda Research And Development Co..Ltd. Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
AU2002227269A1 (en) 2000-11-07 2002-06-03 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
IN192526B (pl) 2001-09-25 2004-04-24 Ranbaxy Lab
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
IL164002A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv Sulfonyl-derivatives as novel inhibitors of histone deacetylase
WO2003087059A2 (en) 2002-04-08 2003-10-23 Sun Pharmaceutical Industries Limited (e)-oxime ether derivative of 5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
EP1578198A1 (en) 2002-12-20 2005-09-28 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
JP2004210716A (ja) 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
WO2004063156A1 (en) 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
DK1622569T3 (en) 2003-04-24 2015-12-14 Incyte Holdings Corp AZA-SPIRO-alkane derivatives as inhibitors of metalloproteases
GB0313766D0 (en) 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
DE602004021611D1 (de) 2003-09-19 2009-07-30 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
EP1745022B1 (en) * 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
US7705017B2 (en) 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
CN1953982B (zh) 2004-05-17 2011-07-06 泰博特克药品有限公司 4-取代-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
JP2008501766A (ja) 2004-06-09 2008-01-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換された三環式のベンゾイミダゾール
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
AR051041A1 (es) 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
WO2006065842A2 (en) 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
CA2596355C (en) 2005-01-31 2015-01-06 Ception Therapeutics, Inc. Tumor necrosis factor inhibitors
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
AR057061A1 (es) 2005-06-16 2007-11-14 Altana Pharma Ag Espiro-bencimidazoles farmaceuticamente activos y su uso en la fabricacion de medicamentos
BRPI0611948A2 (pt) 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
TW200726752A (en) 2005-06-22 2007-07-16 Altana Pharma Ag Process for the production of intermediates for the preparation of tricyclic benzimidazoles
ES2337831T3 (es) 2005-06-24 2010-04-29 Bristol-Myers Squibb Company Derivados de fenilglicinamida y piridilclicinamida utiles como agentes anticoagulantes.
AU2006283876A1 (en) 2005-08-22 2007-03-01 Nycomed Gmbh Isotopically substituted benzimidazole derivatives
EP1940805A4 (en) 2005-08-26 2009-11-11 Methylgene Inc BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2009519998A (ja) 2005-12-19 2009-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノアルコール誘導体の過活動膀胱の治療の為の使用
DE102005061655A1 (de) 2005-12-22 2007-06-28 Merck Patent Gmbh Diazepinone
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2007109178A2 (en) 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
EP2010529A1 (en) 2006-04-10 2009-01-07 PainCeptor Pharma Corp. Compositions and methods for modulating gated ion channels
AU2007297573A1 (en) 2006-06-12 2008-03-27 Viamet Pharmaceuticals, Inc. Metallo-hydrolase inhibitors using metal binding moieties in combination with targeting moieties
TW200808707A (en) 2006-06-14 2008-02-16 Methylgene Inc Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
CN101108859A (zh) 2006-07-17 2008-01-23 上海恒瑞医药有限公司 长春碱类化合物、其制备方法及其在医药上的用途
CN101495186A (zh) 2006-07-26 2009-07-29 诺瓦提斯公司 十一异戊二烯基焦磷酸酯合酶的抑制剂
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
WO2008046155A1 (en) 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
PL2343286T3 (pl) 2006-10-28 2015-06-30 Methylgene Inc Pochodne dibenzo[b,f][1,4]oksazepiny jako inhibitory deacetylazy histonowej
CN101553475B (zh) 2006-10-30 2013-04-24 色品疗法有限公司 作为组蛋白脱乙酰基酶抑制剂的异羟肟酸
US20110150825A1 (en) 2006-11-14 2011-06-23 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
WO2008060721A1 (en) 2006-11-14 2008-05-22 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of t-cell proliferative disorders
CA2673108A1 (en) 2006-12-08 2008-06-19 Merck & Co., Inc. Constrained spirocyclic compounds as cgrp receptor antagonists
WO2008071765A1 (en) 2006-12-14 2008-06-19 Nycomed Gmbh Pharmaceutically active spiro-substituted benzimidazole derivatives
WO2008074858A1 (en) 2006-12-21 2008-06-26 Nycomed Gmbh Intermediates and process for the production of 5-substituted tricyclic benzimidazoles
CA2677649A1 (en) 2007-02-09 2008-08-21 Forest Laboratories Holdings Limited Bioavailable formulations of heterocyclic compounds
WO2008101186A1 (en) 2007-02-15 2008-08-21 The J. David Gladstone Institutes Inhibitors for hdac8
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
AR067329A1 (es) 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
US8148380B2 (en) 2007-07-23 2012-04-03 Crestone, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
CA2714888C (en) 2008-01-09 2017-03-14 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
US20110098267A1 (en) 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
JP2009191041A (ja) 2008-02-18 2009-08-27 Univ Of Tokyo ヒドロキシメチルケトン誘導体
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8980877B2 (en) 2008-04-15 2015-03-17 Dac S.R.L. Spirocyclic derivatives as histone deacetylase inhibitors
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
EP2311840A1 (en) 2009-10-13 2011-04-20 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009137503A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
EP2303888B1 (en) 2008-06-12 2015-05-06 President and Fellows of Harvard College Compounds for antimicrobial intervention
WO2009152210A2 (en) 2008-06-12 2009-12-17 National Health Research Institutes Coumarin compounds and their use for treating cancer
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
PE20110805A1 (es) 2008-09-11 2011-11-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso
WO2010042475A1 (en) 2008-10-07 2010-04-15 Schering Corporation Spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
MX2011003598A (es) 2008-10-14 2011-04-27 Astrazeneca Ab Compuestos heteroaromaticos espirociclicos, fusionados, para el tratamiento de infecciones bacterianas.
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
EP2350029A1 (en) 2008-10-15 2011-08-03 Gilead Sciences, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US8569336B2 (en) 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PL2364983T3 (pl) 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
WO2010088408A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor antagonists for the treatment of neurological conditions
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
KR20130140219A (ko) 2009-03-27 2013-12-23 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 복제의 억제제
JP5643290B2 (ja) 2009-04-09 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｉｖ複製の阻害薬
WO2010125469A1 (en) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CA2765678A1 (en) 2009-06-22 2010-12-29 Christopher Blackburn Substituted hydroxamic acids and uses thereof
US9125901B2 (en) 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
EP2266985A1 (en) 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
ES2736200T3 (es) 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
US20110071136A1 (en) 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc Novel tricyclic protein kinase modulators
SG10201405049RA (en) 2009-09-28 2014-10-30 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
RU2557658C2 (ru) 2009-09-28 2015-07-27 Ф.Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и способы применения
EP2305643A1 (en) 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
WO2011079036A1 (en) 2009-12-22 2011-06-30 The Translational Genomics Research Institute Benzamide derivatives
US8198290B2 (en) 2009-12-23 2012-06-12 Berry And Associates, Inc. Methoxatin derivatives
EP2638009A4 (en) 2010-01-08 2014-06-11 Harvard College FLUORINATED HDAC HEMMER AND USES THEREOF
CA2787018A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Inhibitors of histone deacetylase (hdac) enzymes
JP2011148714A (ja) 2010-01-19 2011-08-04 Nippon Soda Co Ltd 病害防除方法
SI2526093T1 (sl) 2010-01-22 2016-10-28 Acetylon Pharmaceuticals, Inc. Reverzne amidne spojine kot inhibitorji protein deacetilaze in postopki njihove uporabe
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2011106627A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20110212969A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011130163A1 (en) 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2012012320A1 (en) 2010-07-19 2012-01-26 Millenium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20120015943A1 (en) 2010-07-19 2012-01-19 Millennium Pharmacuticals, Inc. Substituted hydroxamic acids and uses thereof
US20130210899A1 (en) 2010-07-30 2013-08-15 The Regents Of The University Of California Method and Therapeutic for the Treatment and Regulation of Memory Formation
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
RU2577861C2 (ru) 2010-09-09 2016-03-20 Ф. Хоффманн-Ля Рош Аг N-гидрокси-бензамиды для лечения рака
AU2011311531B2 (en) 2010-10-08 2014-11-20 Life Sciences Research Partners Vzw HDAC inhibitors to treat Charcot-Marie-Tooth disease
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CN107011311A (zh) 2010-10-22 2017-08-04 斯特拉斯堡大学 用于治疗HSP90相关病状的Pochoxime缀合物
MX2013005392A (es) 2010-11-16 2013-07-29 Acetylon Pharmaceuticals Inc Compuestos de hidroxiamida pirimidina como inhibidores de la proteina deacetilasa y metodo de uso de estos.
CN102558200A (zh) 2010-12-21 2012-07-11 复旦大学 长春碱类衍生物、其制备方法及其在医药上的用途
WO2012085003A1 (en) 2010-12-22 2012-06-28 Katholieke Universiteit Leuven, K.U. Leuven R&D 2-hydroxyisoquinoline-1,3(2h,4h)-diones and related compounds useful as hiv replication inhibitors
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
EP2675276A4 (en) 2011-02-14 2014-08-13 Alkermes Inc PERIPHERAL MY OPIOID ANTAGONISTS
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012110860A1 (en) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2012117421A1 (en) * 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
MX340013B (es) 2011-03-21 2016-06-22 Hoffmann La Roche Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
CN102838625B (zh) 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
WO2012178208A2 (en) 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
AU2012282107A1 (en) 2011-07-08 2014-02-27 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
EA032526B1 (ru) 2011-08-30 2019-06-28 Схди Фаундейшн, Инк. Применение ингибитора кинуренин-3-монооксигеназы для лечения заболеваний и состояний, опосредованных активностью кинуренин-3-монооксигеназы
EP2758406A1 (en) 2011-09-21 2014-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2013049725A2 (en) 2011-09-30 2013-04-04 Tufts University Methods of using adenosine a1 receptor activation for treating depression
US9499479B2 (en) 2011-10-03 2016-11-22 The Trustees Of Columbia University In The City Of New York Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
EP2769422B9 (en) 2011-10-18 2017-03-22 École Polytechnique Fédérale de Lausanne (EPFL) Compounds for electrochemical and/or optoelectronic devices
WO2013059582A2 (en) 2011-10-20 2013-04-25 Nupotential, Inc. Small molecule inhibitors of histone deacteylases
RS57248B1 (sr) 2011-12-11 2018-07-31 Viamet Pharmaceuticals Nc Inc Jedinjenja inhibitori metaloenzima
WO2013088243A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
EP2822926A4 (en) 2012-03-07 2015-11-04 H Lee Moffitt Cancer Ct & Res SELECTIVE HISTON DEACTY LASE-6 HEMMER
GB2503789A (en) 2012-05-15 2014-01-08 Syngenta Participations Ag Quinazoline derivatives as antifungal agents
CN104507902A (zh) 2012-07-10 2015-04-08 佐治亚州立大学研究基金会公司 蒽醌类似物以及其制备和使用方法
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014018919A1 (en) 2012-07-27 2014-01-30 The Regents Of The University Of California Seriniquinones, melanoma-specific anticancer agents
BR112015004648A2 (pt) 2012-09-05 2017-07-04 Bayer Cropscience Ag amidas de ácidos bicicloaril carboxílicos com atividade herbicida
JP6276277B2 (ja) 2012-09-28 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質阻害性の５−アリールトリアゾロアゼピン
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
JP6321685B2 (ja) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
JP6117430B2 (ja) 2013-04-29 2017-04-19 チョン クン ダン ファーマシューティカル コーポレーション 選択的ヒストン脱アセチル化酵素抑制剤としての新規化合物およびこれを含む薬剤学的組成物
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
ES2862126T3 (es) 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
KR101697518B1 (ko) 2014-03-12 2017-01-19 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
PL3292116T3 (pl) 2015-02-02 2022-02-21 Valo Health, Inc. 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
GB201505133D0 (en) * 2015-03-26 2015-05-06 Egerton Charles E And Scott Harden Simon Self-propelled water board apparatus
WO2016168598A1 (en) 2015-04-17 2016-10-20 Forma Therapeutics, Inc. 3-spirocyclic-6-hydroxamic acid tetralins as hdac inhibitors
EP3362445B1 (en) 2015-10-12 2023-01-25 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors

Also Published As

Publication number Publication date
US10421731B2 (en) 2019-09-24
CA2975605C (en) 2023-12-12
US20160221973A1 (en) 2016-08-04
KR102633628B1 (ko) 2024-02-02
CN107873023A (zh) 2018-04-03
US10464910B2 (en) 2019-11-05
US20210009539A1 (en) 2021-01-14
US20200048212A1 (en) 2020-02-13
AU2016215431B2 (en) 2020-07-23
EP3292116B8 (en) 2021-11-24
US10829462B2 (en) 2020-11-10
EP3292116B1 (en) 2021-10-20
US11891365B2 (en) 2024-02-06
IL279830B (en) 2022-08-01
HK1253322A1 (zh) 2019-06-14
WO2016126722A1 (en) 2016-08-11
TW202136220A (zh) 2021-10-01
US20190016692A1 (en) 2019-01-17
MY191591A (en) 2022-06-30
US10214501B2 (en) 2019-02-26
TW201636334A (zh) 2016-10-16
EP4015514A1 (en) 2022-06-22
HUE057623T2 (hu) 2022-05-28
US10421732B2 (en) 2019-09-24
US20210009538A1 (en) 2021-01-14
CA2990165C (en) 2023-12-12
US10494354B2 (en) 2019-12-03
EA201791747A1 (ru) 2018-01-31
TWI768557B (zh) 2022-06-21
US20190119231A1 (en) 2019-04-25
US20190119227A1 (en) 2019-04-25
IL255111B (en) 2021-01-31
CO2017007863A2 (es) 2017-10-20
US20190119234A1 (en) 2019-04-25
MX2020003488A (es) 2022-05-24
US20190112282A1 (en) 2019-04-18
US10494352B2 (en) 2019-12-03
US20190112283A1 (en) 2019-04-18
US20190119232A1 (en) 2019-04-25
MX2017009950A (es) 2017-11-23
US20160221972A1 (en) 2016-08-04
US20220204461A1 (en) 2022-06-30
US10479772B2 (en) 2019-11-19
US20190112284A1 (en) 2019-04-18
WO2016126721A1 (en) 2016-08-11
BR112017016493B1 (pt) 2023-12-12
TW202110813A (zh) 2021-03-16
CA2990165A1 (en) 2016-08-11
IL253652A0 (en) 2017-09-28
US10464909B2 (en) 2019-11-05
MA42032A (fr) 2018-03-14
US10214500B2 (en) 2019-02-26
SG11201706146UA (en) 2017-08-30
SA517382027B1 (ar) 2021-06-15
US10457652B2 (en) 2019-10-29
US10442776B2 (en) 2019-10-15
US20160222028A1 (en) 2016-08-04
TWI697486B (zh) 2020-07-01
CN107801396B (zh) 2021-10-22
TW201643145A (zh) 2016-12-16
TW201636333A (zh) 2016-10-16
US20160222022A1 (en) 2016-08-04
US20190112279A1 (en) 2019-04-18
SG10202100916PA (en) 2021-02-25
US20190119228A1 (en) 2019-04-25
US10428031B2 (en) 2019-10-01
PT3292116T (pt) 2022-01-14
US20200002298A1 (en) 2020-01-02
SG11201708622UA (en) 2017-11-29
US20210009540A1 (en) 2021-01-14
EP3253747B1 (en) 2019-11-27
US10450283B2 (en) 2019-10-22
US10494353B2 (en) 2019-12-03
WO2016126725A1 (en) 2016-08-11
CN114057765A (zh) 2022-02-18
US11279681B2 (en) 2022-03-22
US10494351B2 (en) 2019-12-03
US20190062288A1 (en) 2019-02-28
TWI712591B (zh) 2020-12-11
CA2975605A1 (en) 2016-08-11
US11274085B2 (en) 2022-03-15
TWI776156B (zh) 2022-09-01
US10377726B2 (en) 2019-08-13
AU2016215431A1 (en) 2018-01-18
EP3253747A1 (en) 2017-12-13
IL253652B (en) 2021-03-25
DK3292116T3 (da) 2022-01-10
EA036711B1 (ru) 2020-12-10
PH12017501383A1 (en) 2018-01-08
US10239845B2 (en) 2019-03-26
US20220363651A1 (en) 2022-11-17
CN107873023B (zh) 2021-07-23
US20190112280A1 (en) 2019-04-18
US11274084B2 (en) 2022-03-15
ES2903523T3 (es) 2022-04-04
AU2020260523A1 (en) 2020-11-26
US10450284B2 (en) 2019-10-22
US10822316B2 (en) 2020-11-03
IL280856B (en) 2022-09-01
ECSP17055491A (es) 2017-11-30
BR112017016493A2 (pt) 2018-04-10
IL255111A (en) 2018-02-28
US10112915B2 (en) 2018-10-30
JP2018503674A (ja) 2018-02-08
CN107801396A (zh) 2018-03-13
US20190119235A1 (en) 2019-04-25
SG10202100915RA (en) 2021-02-25
AU2020257136A1 (en) 2020-11-19
US10988450B2 (en) 2021-04-27
CL2017001968A1 (es) 2018-04-13
US10472337B2 (en) 2019-11-12
US10414738B2 (en) 2019-09-17
JP6668362B2 (ja) 2020-03-18
AU2016215432B2 (en) 2020-07-30
US20190119229A1 (en) 2019-04-25
US10829461B2 (en) 2020-11-10
US20190119233A1 (en) 2019-04-25
KR20170122759A (ko) 2017-11-06
IL280856A (en) 2021-04-29
ES2770123T3 (es) 2020-06-30
WO2016126724A1 (en) 2016-08-11
US20190016693A1 (en) 2019-01-17
US10513501B2 (en) 2019-12-24
US10501424B2 (en) 2019-12-10
US20200055830A1 (en) 2020-02-20
HK1251550A1 (zh) 2019-02-01
EA201792673A1 (ru) 2018-04-30
AU2016215432A1 (en) 2017-08-17
EP3292116A1 (en) 2018-03-14
US20190112281A1 (en) 2019-04-18
US20190119230A1 (en) 2019-04-25
US20200048211A1 (en) 2020-02-13
TW201629026A (zh) 2016-08-16
US20190127339A1 (en) 2019-05-02
IL279830A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
IL280856A (en) 3-Alkyl-4-amino-[0,5,4] bicyclic hydroxamic acids as HDAC inhibitors
IL282103B1 (en) Furinones as ubiquitin-specific protease 1 inhibitors
HK1259073A1 (zh) 作為己酮糖激酶抑制劑的被取代的3-氮雜雙環[3‧1‧0]己烷
HK1245266A1 (zh) 作為usp30抑制劑的1-氰基吡咯烷化合物
HK1248222A1 (zh) 噻吩並嘧啶酮作為泛素特異性蛋白酶7抑制劑
EP3303324A4 (en) Novel corrosion inhibitors
IL265138B (en) Dopamine-b-hydroxylase inhibitors that penetrate the blood-brain barrier
EP3139918A4 (en) Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
EP3153582A4 (en) Improved nitrile hydratase
IL255024A0 (en) Hydroxamic acids and their uses
GB201616201D0 (en) Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
GB201521588D0 (en) Fft 1
GB201520946D0 (en) Active tagging
AU2015901305A0 (en) Improved anchor point